Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease
- PMID: 24833897
- PMCID: PMC4014384
- DOI: 10.2147/COPD.S51012
Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease that affects an estimated 10% of the world's population over the age of 40 years. Worldwide, COPD ranks in the top ten for causes of disability and death. Given the significant impact of this disease, it is important to note that acute exacerbations of COPD (AECOPD) are by far the most costly and devastating aspect of disease management. Systemic steroids have long been a standard for the treatment of AECOPD; however, the optimal strategy for dosing and administration of these medications continues to be debated.
Objective: To review the use of corticosteroids in the treatment of acute exacerbations of COPD.
Materials and methods: Literature was identified through PubMed Medline (1950-February 2014) and Embase (1950-February 2014) utilizing the search terms corticosteroids, COPD, chronic bronchitis, emphysema, and exacerbation. All reference citations from identified publications were reviewed for possible inclusion. All identified randomized, placebo-controlled trials, meta-analyses, and systematic reviews evaluating the efficacy of systemic corticosteroids in the treatment of AECOPD were reviewed and summarized.
Results: The administration of corticosteroids in the treatment of AECOPD was assessed. In comparison to placebo, systemic corticosteroids improve airflow, decrease the rate of treatment failure and risk of relapse, and may improve symptoms and decrease the length of hospital stay. Therefore, corticosteroids are recommended by all major guidelines in the treatment of AECOPD. Existing literature suggests that low-dose oral corticosteroids are as efficacious as high-dose, intravenous corticosteroid regimens, while minimizing adverse effects. Recent data suggest that shorter durations of corticosteroid therapy are as efficacious as the traditional treatment durations currently recommended by guidelines.
Conclusion: Systemic corticosteroids are efficacious in the treatment of AECOPD and considered a standard of care for patients experiencing an AECOPD. Therefore, systemic corticosteroids should be administered to all patients experiencing AECOPD severe enough to seek emergent medical care. The lowest effective dose and shortest duration of therapy should be considered.
Keywords: chronic obstructive pulmonary disease; exacerbation.
Similar articles
-
Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial).Trials. 2019 Dec 16;20(1):727. doi: 10.1186/s13063-019-3856-8. Trials. 2019. PMID: 31842993 Free PMC article.
-
Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.Int J Chron Obstruct Pulmon Dis. 2018 May 10;13:1515-1525. doi: 10.2147/COPD.S149669. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29785101 Free PMC article. Clinical Trial.
-
Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.Respir Res. 2021 May 21;22(1):155. doi: 10.1186/s12931-021-01745-5. Respir Res. 2021. PMID: 34020641 Free PMC article.
-
Systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease.Am J Health Syst Pharm. 2010 Jul 1;67(13):1061-9. doi: 10.2146/ajhp090293. Am J Health Syst Pharm. 2010. PMID: 20554591 Review.
-
Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials.Clin Respir J. 2013 Oct;7(4):305-18. doi: 10.1111/crj.12008. Epub 2012 Nov 28. Clin Respir J. 2013. PMID: 23072733 Review.
Cited by
-
Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.PLoS One. 2017 Nov 27;12(11):e0188644. doi: 10.1371/journal.pone.0188644. eCollection 2017. PLoS One. 2017. PMID: 29176905 Free PMC article.
-
Corticosteroid Resistance in Smokers-A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial.J Clin Med. 2021 Jun 21;10(12):2734. doi: 10.3390/jcm10122734. J Clin Med. 2021. PMID: 34205765 Free PMC article.
-
Dual Role of microRNA-146a in Experimental Inflammation in Human Pulmonary Epithelial and Immune Cells and Expression in Inflammatory Lung Diseases.Int J Mol Sci. 2024 Jul 13;25(14):7686. doi: 10.3390/ijms25147686. Int J Mol Sci. 2024. PMID: 39062931 Free PMC article.
-
Immunoproteasome dysfunction augments alternative polarization of alveolar macrophages.Cell Death Differ. 2016 Jun;23(6):1026-37. doi: 10.1038/cdd.2016.3. Epub 2016 Mar 18. Cell Death Differ. 2016. PMID: 26990663 Free PMC article.
-
Berberine Attenuates Cigarette Smoke Extract-induced Airway Inflammation in Mice: Involvement of TGF-β1/Smads Signaling Pathway.Curr Med Sci. 2019 Oct;39(5):748-753. doi: 10.1007/s11596-019-2101-8. Epub 2019 Oct 14. Curr Med Sci. 2019. PMID: 31612392
References
-
- Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523–532. - PubMed
-
- National Heart, Lung, and Blood Institute . Morbidity and Mortality: Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health; 2012. [Accessed March 17, 2014]. Available from: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm.
-
- Mathers C, Boerma T, Fat DM. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008.
-
- Murphy SL, Xu JQ, Kochanek KD. Death: preliminary data for 2008. Natl Vital Stat Rep. 2012;60:1–51. - PubMed
-
- global initiative for chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Bethesda (MD): 2013. [Accessed March 17, 2014]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical